Foundations01
Human researchWhat Is Retatrutide? A Guide to the Molecule and Its Three Receptors
Understand what retatrutide is, how its receptor targets differ, and where mechanism ends and clinical evidence begins.
4 min read · 5 sources
THE RETATRUTIDE EXPLAINER
One molecule.
Three receptor targets.
What is retatrutide?Understand retatrutide, triple agonism, published clinical studies and its investigational status, with original sources.
3 In-depth guides01 Minute to explore100% Source linked
THE RECEPTOR MAP
Count the targets.Then read the outcomes.
GIP · GLP-1 · Glucagon
EXPLAINER / CHECKED 09 NOV 2026INFORMED READING. ORIGINAL SOURCES. OPEN QUESTIONS.
A BETTER WAY TO READ
The answer is in the details.
Retatrutide is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. That makes it a triple receptor agonist. The description identifies a mechanism; the clinical studies determine what outcomes were observed in particular groups of people.
This focused explainer follows the molecule from receptor pharmacology to human trials. It separates discovery experiments, published phase 2 and phase 3 findings, and regulatory status. A later development stage is not itself an approval decision.
The guides combine Echo Peptides’ research background with the original retatrutide papers and current official information. They explain the language without implying that a research-vial product is the medicine used in a clinical trial.
01Define triple agonism
02Read the human trials
03Check the current status
START WITH ONE
GOOD QUESTION.REHUMAN RESEARCH / 4 MIN READ
GOOD QUESTION.REHUMAN RESEARCH / 4 MIN READ
THE STARTING POINT
What Is Retatrutide? A Guide to the Molecule and Its Three Receptors
Retatrutide is an investigational peptide designed to activate three hormone receptors: GIP, GLP-1 and glucagon. Its development name is LY3437943. Calling it a triple agonist describes this receptor activity; it does not mean three separate medicines are mixed together, or that three times the benefit has been established. The molecule is being evaluated in clinical trials, and its current regulatory status must be kept separate from the results those trials report.
Read the guideTHE READING COLLECTION
3 in-depth guidesFollow your curiosity.
Sources linked in every article
Trial results02
Human researchRetatrutide Results: What Changed Between Phase 2 and Phase 3?
Read the retatrutide results by population, endpoint, time point and estimand instead of comparing isolated headline percentages.
4 min read · 5 sources
Regulatory context03
SafetyIs Retatrutide Approved? Status, Trial Records and Participation
Understand current regulatory status, what a clinical-trial listing means and how to read official participation information.
5 min read · 7 sources
Read the finding. Follow the source. Keep the limitation.Open the study desk
THREE QUESTIONS TO KEEP ASKINGInteresting science.
Interesting science.
Honest boundaries.
Research becomes more useful when the observation and the interpretation stay connected.
Explore the study deskWhat could happen?
Receptor activity, cell experiments and biological pathways can explain a reason to investigate. They do not by themselves establish a benefit in people.
What was actually measured?
Keep the population, comparator, timeframe and endpoint attached to the result. A number is informative when its context travels with it.
What remains unanswered?
A good explanation names uncertainty. Other populations, longer exposure and different formulations may require separate evidence.
QUESTIONS, IN CONTEXTA clear place
A clear place
to begin.
Short answers, with a longer reading path.
What is retatrutide?+
Retatrutide, also called LY3437943, is an investigational engineered peptide with agonist activity at GIP, GLP-1 and glucagon receptors.
Is retatrutide FDA approved?+
As checked on 9 November 2026, retatrutide remains investigational and is not an ingredient in an FDA-approved drug. A published clinical trial does not by itself establish regulatory approval.
Is retatrutide the same as tirzepatide?+
No. Tirzepatide has GIP and GLP-1 receptor activity; retatrutide adds glucagon receptor activity. The target map does not establish a clinical ranking between them.
Research materials and research evidence answer different questions. Explore our connected brands with that distinction in mind.